Search results for "evidence"

showing 10 items of 1050 documents

Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of …

2016

The recent advances in identification of the molecular mechanisms related to tumorigenesis and angiogenesis, along with the understanding of molecular alterations involved in renal cell carcinoma (RCC) pathogenesis, has allowed the development of several new drugs which have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). This process has resulted in clinically significant improvements in median overall survival and an increasing number of patients undergoes two or even three lines of therapy. Therefore, it is necessary a long-term perspective of the treatment: planning a sequential and personalized therapeutic strategy to improve clinical outcome, the potential to a…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practicemedicine.drug_classSettore MED/06 - Oncologia MedicaVEGF receptorsAntineoplastic AgentsReviewurologic and male genital diseasesrenal cell cancerTyrosine-kinase inhibitor03 medical and health sciencesangiogenesis0302 clinical medicinetyrosine kinase inhibitorQuality of lifeRenal cell carcinomaInternal medicineAngiogenesis; MTOR; Renal cell cancer; Tyrosine kinase inhibitor; VEGFr; OncologymedicineOverall survivalAnimalsHumansMolecular Targeted TherapyPrecision MedicineCarcinoma Renal CellTherapeutic strategybiologybusiness.industryPrecision medicinemedicine.diseaseKidney NeoplasmsSurgeryAngiogenesiSettore MED/18 - Chirurgia GeneraleVEGFr030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinmTORbusiness
researchProduct

Reprint of "EXOSOME LEVELS IN HUMAN BODY FLUIDS: A TUMOR MARKER BY THEMSELVES?"

2017

Despite considerable research efforts, the finding of reliable tumor biomarkers remains challenging and unresolved. In recent years a novel diagnostic biomedical tool with high potential has been identified in extracellular nanovesicles or exosomes. They are released by the majority of the cells and contain detailed molecular information on the cell of origin including tumor hallmarks. Exosomes can be isolated from easy accessible body fluids, and most importantly, they can at once provide with several biomarkers, with different levels of specificity. Recent clinical evidence shows that the levels of exosomes released into body fluids may by themselves represent a predictive/diagnostic of t…

0301 basic medicinePharmaceutical ScienceExosomesExosome03 medical and health sciencesProstate cancerTumor Biomarkers0302 clinical medicineMedicineHigh potentialTumor markerProstate cancerbusiness.industryFollow-upCancerExtracellular vesiclesEarly diagnosismedicine.diseaseMicrovesiclesBody fluids030104 developmental biologyClinical evidence030220 oncology & carcinogenesisImmunologyCancer researchbusinessBiomarkersEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The habitual nature of food purchases at the supermarket: Implications for policy making

2020

Abstract Supermarkets have become the most important provider of food products worldwide. However, empirical evidence about how consumers make their food purchase decisions in this environment is still scarce. The present field study aimed to: i) explore how people make their in-store food purchases, and ii) identify the information they search for when making those purchases. Consumers (n = 144) were intercepted when entering the facilities of three supermarkets in two Uruguayan cities. They were asked to wear a mobile eye-tracker while they made their purchases as they normally do. The great majority of the consumers bought at least one food product or beverage (92%) and, on average, exam…

0301 basic medicinePoint of salePolicy makingPsychological intervention030209 endocrinology & metabolismContext (language use)computer.software_genreHealthful foodBeveragesFood Preferences03 medical and health sciences0302 clinical medicineHumansSupermarketsPolicy MakingEmpirical evidenceGeneral Psychology030109 nutrition & dieteticsNutrition and DieteticsAdvertisingConsumer BehaviorProduct (business)Shopping basketFoodBusinesscomputerAppetite
researchProduct

Ancient pigs reveal a near-complete genomic turnover following their introduction to Europe

2019

International audience; Archaeological evidence indicates that pig domestication had begun by ∼10,500 y before the present (BP) in the Near East, and mitochondrial DNA (mtDNA) suggests that pigs arrived in Europe alongside farmers ∼8,500 y BP. A few thousand years after the introduction of Near Eastern pigs into Europe, however, their characteristic mtDNA signature disappeared and was replaced by haplotypes associated with European wild boars. This turnover could be accounted for by substantial gene flow from local Euro-pean wild boars, although it is also possible that European wild boars were domesticated independently without any genetic contribution from the Near East. To test these hyp…

0301 basic medicineSwine[SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropologySkin Pigmentation[SHS]Humanities and Social SciencesGene flowDomesticationddc:590BREEDSDOMESTIC PIGS/dk/atira/pure/subjectarea/asjc/1000HISTORY0601 history and archaeologyNeolithicHistory AncientPhylogenyMultidisciplinary060102 archaeologyINTROGRESSIONEurope ; pigs ; domestication ; genomesWILD06 humanities and the artsArchaeological evidenceGene flowEuropeSPREADCoatMitochondrial DNAEvolutionZoology930Locus (genetics)BiologyAnimal Breeding and GenomicsDNA MitochondrialMiddle East03 medical and health sciencesAnimalsFokkerij en GenomicaDNA AncientGeneralDomesticationddc:930HaplotypeDNA900 Geschichte und Geografie::930 Geschichte des Altertums (bis ca. 499) Archäologie::930 Geschichte des Altertums bis ca. 499 ArchäologieLONGSIZE030104 developmental biologydomestication evolution gene flow NeolithicWIAS
researchProduct

Elderly Onset Celiac Disease: A Narrative Review.

2016

Celiac sprue is a chronic disease, which usually occurs in children and young adults. However, it can develop in any age group, and the prevalence is increasing even in the elderly population. The atypical patterns of clinical presentation in this age group sometimes can cause a delay in diagnosis. Given the lower sensitivity and specificity of serological tests in the aged population, clinical suspect often arises in the presence of complications (autoimmune disorders, fractures, and finally, malignancy) and must be supported by endoscopic and imaging tools. In this review, we highlight the incidence and prevalence of celiac disease in the elderly, the patterns of clinical presentation, d…

0301 basic medicinecardiovascular riskPediatricsmedicine.medical_specialtyEvidence-based practiceSettore MED/09 - Medicina InternaDiseaseReviewMalignancyBioinformaticselderlySprue03 medical and health sciences0302 clinical medicinemedicineYoung adultlcsh:RC799-869cardiovascular risk; celiac disease; elderly; presentationsSettore MED/12 - Gastroenterologiapresentationsbusiness.industryIncidence (epidemiology)Gastroenterologymedicine.disease030104 developmental biologyInformatics030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologyPresentation (obstetrics)businessceliac diseaseClinical medicine insights. Gastroenterology
researchProduct

Galectin-3 in acute coronary syndrome

2017

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This art…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHuman
researchProduct

North African Medicinal Plants Traditionally Used in Cancer Therapy.

2017

Background: Cancer is a major cause of mortality worldwide with increasing numbers by the years. In North Africa, the number of cancer patients is alarming. Also shocking is that a huge number of cancer patients only have access to traditional medicines due to several factors, e.g., economic difficulties. In fact, medicinal plants are widely used for the treatment of several pathologies, including cancer. Truthfully, herbalists and botanists in North African countries prescribe several plants for cancer treatment. Despite the popularity and the potential of medicinal plants for the treatment of cancer, scientific evidence on their anticancer effects are still scarce for most of the describe…

0301 basic medicinemedicine.medical_specialtyAlternative medicineCancer therapyReviewanticancerethnobotanicalScientific evidence03 medical and health sciences0302 clinical medicinemedicinecancerPharmacology (medical)Medicinal plantsPharmacologyTraditional medicinebusiness.industrylcsh:RM1-950Cancerfood and beveragesmedicine.diseaseNorth AfricaClinical trial030104 developmental biologylcsh:Therapeutics. PharmacologyDrug development030220 oncology & carcinogenesisEthnobotanybusinessmedicinal plantsFrontiers in pharmacology
researchProduct

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO…

2017

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account t…

0301 basic medicinemedicine.medical_specialtyChinaColorectal cancerDrug availabilityEthnic groupTaiwanConsensuSystemic therapyScientific evidence03 medical and health sciences0302 clinical medicineAsian PeopleRepublic of KoreaAsian countrymedicineHumansNeoplasm MetastasisReimbursementClinical OncologyClinical practice guidelinePan-Asianbusiness.industryMalaysiaHematologymedicine.diseaseColorectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicinebusinessColorectal NeoplasmsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

2015

BACKGROUND There is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). OBJECTIVE The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. METHODS The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following t…

0301 basic medicinemedicine.medical_specialtyConsensusAttitude of Health PersonnelAlternative medicineDelphi methodGastroenterologyScientific evidence03 medical and health sciences0302 clinical medicineInternal medicinePhysiciansSurveys and QuestionnairesmedicineImmunology and AllergyHumansDisease management (health)Thiopurine methyltransferasebiologybusiness.industryRemission InductionGastroenterologyDisease ManagementEvidence-based medicineDiscontinuation030104 developmental biologyFamily medicinePractice Guidelines as Topicbiology.protein030211 gastroenterology & hepatologyColitis UlcerativeWorking groupbusinessInflammatory bowel diseases
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct